Elena Cubedo

Elena Cubedo

Auto-generated profile, based on publicly available information

Elena Cubedo

Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
EBEVA BANDRES
EVA BANDRES
ECE Cubedo
E Cubedo
XAXabier Agirre
Xabier Agirre
RMR Malumbres
R Malumbres
RZRuth Zarate
Ruth Zarate
Jesus Garcia-FoncillasJesus Garcia-Foncillas
Jesus Garcia-Foncillas
MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles by repressing translation or cleaving RNA transcripts. Although the number of verified human miRNA is still expanding, only few have been functionally described. However, emerging evidences suggest the potential involvement of altered regulation of miRNA in pathogenesis of cancers and these genes are thought to function as both tumours suppressor and oncogenes.

16 April 2009 in Blood
Verified
Journal Article
Open access
PDF file
RMRaquel Malumbres
Raquel Malumbres
Kristopher SarosiekKristopher Sarosiek
Kristopher Sarosiek
ECElena Cubedo
Elena Cubedo
JRJose W. Ruiz
Jose W. Ruiz
XJXiaoyu Jiang
Xiaoyu Jiang
ILIzidore S Lossos
Izidore S Lossos
MiRNAs are small RNA molecules binding to partially complementary sites in the 3′-UTR of target transcripts and repressing their expression. miRNAs orchestrate multiple cellular functions and play critical roles in cell differentiation and cancer development. We analyzed miRNA profiles in B-cell subsets during peripheral B-cell differentiation as well as in diffuse large B-cell lymphoma (DLBCL) cells. Our results show temporal changes in the miRNA expression during B-cell differentiation with a highly unique miRNA profile in germinal center (GC) lymphocytes. We provide experimental evidence that these changes may be physiologically relevant by demonstrating that GC-enriched hsa-miR-125b down-regulates the expression of IRF4 and PRDM1/BLIMP1, and memory B cell–enriched hsa-miR-223 down-regulates the expression of LMO2. We further demonstrate that although an important component of the biology of a malignant cell is inherited from its nontransformed cellular progenitor—GC centroblasts—aberrant miRNA expression is acquired upon cell transformation. A 9-miRNA signature was identified that could precisely differentiate the 2 major subtypes of DLBCL. Finally, expression of some of the miRNAs in this signature is correlated with clinical outcome of uniformly treated DLBCL patients.

1 February 2007 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
LCLucía Cordeu
Lucía Cordeu
ECElena Cubedo
Elena Cubedo
EBEVA BANDRES
EVA BANDRES
ARAmaia Rebollo
Amaia Rebollo
XSXabi Sáenz
Xabi Sáenz
JGJesús García-Foncillas
Jesús García-Foncillas

12 January 2012 in Blood
Verified
Journal Article
Closed access
PDF file
LDLiat Nadav Dagan
Liat Nadav Dagan
XJXiaoyu Jiang
Xiaoyu Jiang
SBShruti Bhatt
Shruti Bhatt
ECElena Cubedo
Elena Cubedo
KRKlaus Rajewsky
Klaus Rajewsky
ILIzidore S. Lossos
Izidore S. Lossos
HGAL, a prognostic biomarker in patients with diffuse large B-cell lymphoma and classic Hodgkin lymphoma, inhibits lymphocyte and lymphoma cell motility by activating the RhoA signaling cascade and interacting with actin and myosin proteins. Although HGAL expression is limited to germinal center (GC) lymphocytes and GC-derived lymphomas, little is known about its regulation. miR-155 is implicated in control of GC reaction and lymphomagenesis. We demonstrate that miR-155 directly down-regulates HGAL expression by binding to its 3′-untranslated region, leading to decreased RhoA activation and increased spontaneous and chemoattractant-induced lymphoma cell motility. The effects of miR-155 on RhoA activation and cell motility can be rescued by transfection of HGAL lacking the miR-155 binding site. This inhibitory effect of miR-155 suggests that it may have a key role in the loss of HGAL expression on differentiation of human GC B cells to plasma cell. Furthermore, this effect may contribute to lymphoma cell dissemination and aggressiveness, characteristic of activated B cell–like diffuse large B-cell lymphoma typically expressing high levels of miR-155 and lacking HGAL expression.

7 June 2012 in Blood
Verified
Journal Article
Open access
PDF file
ECElena Cubedo
Elena Cubedo
AGAndrew J. Gentles
Andrew J. Gentles
CHChuanxin Huang
Chuanxin Huang
YNYasodha Natkunam
Yasodha Natkunam
SBShruti Bhatt
Shruti Bhatt
ILIzidore S Lossos
Izidore S Lossos
LMO2 regulates gene expression by facilitating the formation of multipartite DNA-binding complexes. In B cells, LMO2 is specifically up-regulated in the germinal center (GC) and is expressed in GC-derived non-Hodgkin lymphomas. LMO2 is one of the most powerful prognostic indicators in diffuse large B-cell (DLBCL) patients. However, its function in GC B cells and DLBCL is currently unknown. In this study, we characterized the LMO2 transcriptome and transcriptional complex in DLBCL cells. LMO2 regulates genes implicated in kinetochore function, chromosome assembly, and mitosis. Overexpression of LMO2 in DLBCL cell lines results in centrosome amplification. In DLBCL, the LMO2 complex contains some of the traditional partners, such as LDB1, E2A, HEB, Lyl1, ETO2, and SP1, but not TAL1 or GATA proteins. Furthermore, we identified novel LMO2 interacting partners: ELK1, nuclear factor of activated T-cells (NFATc1), and lymphoid enhancer-binding factor1 (LEF1) proteins. Reporter assays revealed that LMO2 increases transcriptional activity of NFATc1 and decreases transcriptional activity of LEF1 proteins. Overall, our studies identified a novel LMO2 transcriptome and interactome in DLBCL and provides a platform for future elucidation of LMO2 function in GC B cells and DLBCL pathogenesis.

1 March 2005 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Carmen SanmartinCarmen Sanmartin
Carmen Sanmartin
MEMikel Echeverría
Mikel Echeverría
BMBeatriz Mendívil
Beatriz Mendívil
LCLucía Cordeu
Lucía Cordeu
ECElena Cubedo
Elena Cubedo
JPJuan Antonio Palop
Juan Antonio Palop